PALO ALTO, CALIF.--(BUSINESS WIRE)--
Medable Inc., the leading SaaS provider for digital and decentralized clinical trials, today announced Medable TeleCOA™. This new offering combines electronic Clinical Outcome Assessments (eCOAs) with TeleVisits on web and mobile, to enable critical clinical trial outcomes to be captured from the comfort of a patient’s home, anywhere in the world. This industry-first combination will facilitate the transition of eCOAs from clinic-only to remote and decentralized settings, improving patient access and engagement.
Designed with flexibility and modularity, the Medable platform enables study-specific digital workflows for patients and sites for recruitment, screening, consent, and throughout study conduct. Unlike traditional eCOA point solutions that silo data and are tied to in-person visits, Medable TeleCOA allows outcome assessments to be conducted remotely via web and mobile, within a unified digital experience across the entire study workflow. TeleCOA enables a fully remote live interaction between patients and clinicians for remote capture of outcome assessments by allowing a clinician to simultaneously perform the assessment while also evaluating and guiding the patient.
Medable TeleCOA is the latest addition to the Medable digital and decentralized clinical trial platform, which provides a flexible, modular, and compliant suite of cloud-based offerings that allow clinical leaders to right-size their digital approach to meet unique study needs. Medable TeleCOA complements Medable’s existing TeleVisit and TeleConsent offerings by integrating seamlessly to improve the trial experience for patients, sites, and sponsors.
Medable’s suite of telemedicine-enabled offerings have proven critical to clinical trial success during the COVID-19 pandemic, enabling trials to leverage digital tools to accelerate patient access, enrollment, and participation.
“Enabling remote outcome collection is key to expanding access to clinical research,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “We’re excited to break down yet another barrier, and streamline the path to greater participant diversity, access, and engagement.”
Medable has an established and rapidly growing track record of excellence in eCOA, having implemented eCOA globally across phases and therapeutic areas. Medable’s eCOA solution has seen rapid adoption by leading sponsors over the past several years, due to its patient and site-centric design, strong connected and bring-your-own-device support, and implementation speed.
Medable TeleCOA was developed in close dialogue with patients and sites, informed by Medable’s Patient Advisory Council, a nationwide network of advocates who advise Medable and customers on ways to improve patient access, experience, and outcomes. A recent survey of 1,700 patients who had engaged on the Medable platform for web-based teleconsents and eligibility screening visits resulted in a patient satisfaction rating exceeding 95 percent.
“As a health policy wonk by training, a clinical researcher by choice, and optic atrophy patient advocate by necessity, I believe we can learn a great deal from the patient community and incorporate patient perspectives across the clinical trial landscape to accelerate trial timelines,” said Richie Kahn, Medable PAC member. “I’m excited that Medable’s decentralized clinical trial platform and Medable TeleCOA are built with these perspectives in mind. By combining eCOA with TeleVisits on any web-enabled device, Medable has made it much easier to shift onsite visits to remote without sacrificing the most important interactions between patient and investigator.”
Medable TeleCOA was also designed to meet the needs of eCOA scientists and clinicians. TeleCOA enables clinicians to simultaneously interact with participants and administer outcome assessments, something critical to the outcome assessment process.
“For more than 20 years we have dedicated our efforts at Innovaderm to advancing dermatology research,” said Dr. Robert Bissonnette, MD, FRCPC, founder and CEO of Innovaderm. “As the leader of a specialty CRO and as an investigator who has focused exclusively on dermatology, I have seen firsthand how patients and site staff can benefit from decentralized clinical trial methodologies. Medable’s flexible and modular platform means that we can deploy their platform to shift a number of scheduled visits from onsite to remote while still maintaining the patient/investigator relationship that is core to every clinical study.”
Medable is partnering with researchers and scientists who are eCOA copyright holders to validate remote utilization of instruments and assessments. “Validation of remote eCOA science is important and Medable is actively partnering with copyright holders and researchers to ensure that remote assessments are feasible and do not jeopardize the quality of the assessment or instrument,” said Longmire.
Please click here to register for a live webinar November 18, titled “eCOA in a Decentralized World: Enable Remote Collection of Outcomes to Improve Study Access and Engagement.”
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. For more information, visit www.medable.com and follow @Medableinc on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005390/en/
Copyright Business Wire 2020